Results 121 to 130 of about 14,309 (181)

A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. [PDF]

Leukemia, 2019
Mascarenhas J, Kosiorek H, Prchal J, Yacoub A, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Salama ME, Weinberg RS, Rampal R, Goldberg JD, Mesa R, Dueck AC, Hoffman R.   +31 more
europepmc   +1 more source

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.

Blood, 2019
Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Papaemmanuil E, Salama M, Singer-Weinberg R, Rampal R, Goldberg JD, Barbui T, Mesa R, Dueck AC, Hoffman R.   +33 more
europepmc   +1 more source

Immunotherapy with imiquimod and interferon alfa for metastasized Merkel cell carcinoma. [PDF]

Curr Oncol, 2016
Wahl RU, Braunschweig T, Ghassemi A, Rübben A.   +3 more
europepmc   +1 more source

Between the classic hit and the modern sequel: transition dosing between peginterferon alfa-2a and ropeginterferon alfa-2b for myeloproliferative neoplasms. [PDF]

Ann Hematol
Abu-Zeinah G, Hobbs G, Reeves BN, Yacoub A, Scandura JM.   +4 more
europepmc   +1 more source

Hematologic and molecular response to ropeginterferon alfa-2b in patients with polycythemia vera: a systematic review and meta-analysis. [PDF]

Ann Hematol
Elgadi A, Wagealla M, Noorallah T, Esmail R, Almahi SS.   +4 more
europepmc   +1 more source

Interferon alfa-2b in the management of recurrent conjunctival papillomatosis.

Indian J Ophthalmol, 2016
Singh M, Gautam N, Gupta A, Kaur M.
europepmc   +1 more source

Ropeginterferon dose-escalation strategies in polycythemia vera: a systematic review and meta-analysis. [PDF]

BMC Cancer
Yoon SY, Park S, Jeong SY, Lee MY, Kim KH, Lee N, Won JH, Lee SE.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Interferon Alfa for Macular Degeneration

Annals of Pharmacotherapy, 1996
Clinical studies demonstrate that interferon alfa has little benefit in treating CNV secondary to macular degeneration. However, it may be useful in the treatment of choroidal and retinal hemangiomas, diabetic and post-vein occlusion retinopathy, and retinopathy of prematurity.
S L, Williford, T, King
openaire   +2 more sources